본문 바로가기
HOME> 저널/프로시딩 > 저널/프로시딩 검색상세

저널/프로시딩 상세정보

권호별목차 / 소장처보기

H : 소장처정보

T : 목차정보

Current opinion in pharmacology 19건

  1. [해외논문]   Editorial overview: Cardiovascular and renal: Novel therapies in peripheral artery disease   SCIE

    Oikonomou, Evangelos , Tousoulis, Dimitris
    Current opinion in pharmacology v.39 ,pp. iv - vi , 2018 , 1471-4892 ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  2. [해외논문]   Contents   SCIE


    Current opinion in pharmacology v.39 ,pp. iii - iii , 2018 , 1471-4892 ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  3. [해외논문]   Editorial board   SCIE


    Current opinion in pharmacology v.39 ,pp. i - i , 2018 , 1471-4892 ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  4. [해외논문]   Anti-inflammatory agents in peripheral arterial disease   SCIE

    Antonopoulos, Alexios S , Papanikolaou, Evi , Vogiatzi, Georgia , Oikonomou, Evangelos , Tousoulis, Dimitris
    Current opinion in pharmacology v.39 ,pp. 1 - 8 , 2018 , 1471-4892 ,

    초록

    Inflammation is pivotally involved in coronary and peripheral atherosclerotic disease. This established concept is based on both experimental animal models of vascular inflammation and Mendelian randomization studies demonstrating a causal relationship between pro-inflammatory cytokines (e.g. interleukin-6) and cardiovascular disease risk. More recently, the reduction of cardiovascular events by use of an interleukin-1β inhibitor (canakinumab) has revived interest in the use of anti-inflammatory agents for the treatment of atherosclerotic disease, including peripheral arterial disease. In this mini review article we provide an update on the pleiotropic anti-inflammatory properties of approved drugs for use in cardiovascular disease (e.g. antiplatelets, statins, PCSK9 inhibitors) and discuss the role of targeted or untargeted anti-inflammatory atheroprotection in peripheral arterial disease by agents such as colchicine, methotrexate, anti-TNF-α agents and monoclonal antibodies against interleukin-signaling. Highlights Existing cardiovascular drugs yield secondary benefits by reducing inflammation. Broad-based or targeted anti-inflammatory treatment of atherosclerosis is promising. Canakinumab, monoclonal antibody against IL-1β treatment in coronary patients reduced cardiovascular events. More evidence is needed on antiinflammatory agents use in PAD. The field of immunomodulation in atherosclerosis treatment is rapidly evolving.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  5. [해외논문]   Coronary versus carotid artery plaques. Similarities and differences regarding biomarkers morphology and prognosis   SCIE

    Sigala, Fragiska (1st Department of Propaedeutic Surgery, University of Athens Medical School, Hippocration Hospital, Athens, Greece ) , Oikonomou, Evangelos (1st Department of Propaedeutic Surgery, University of Athens Medical School, Hippocration Hospital, Athens, Greece ) , Antonopoulos, Alexis S (1st Cardiology Clinic, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece ) , Galyfos, George (1st Department of Propaedeutic Surgery, University of Athens Medical School, Hippocration Hospital, Athens, Greece ) , Tousoulis, Dimitris (1st Cardiology Clinic, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece)
    Current opinion in pharmacology v.39 ,pp. 9 - 18 , 2018 , 1471-4892 ,

    초록

    Carotid and coronary artery disease are two major atherosclerotic conditions that have shown an increased prevalence in the last three decades that is associated with high morbidity and mortality. Recent data have revealed that the development of the atherosclerotic plaque—the basic entity in both diseases—may share similar characteristics and mechanisms irrespective of the location site. Even though the biology of atherosclerotic process is similar, there are differences in plaque morphology and characteristics. Indeed, plaque erosion, calcified nodules, fibrous cap thickness and macrophage accumulation may be different in the setting of coronary and carotid artery disease. The perivascular adipose tissue surrounding the coronary arteries (but not carotids) could also affect plaque biology. In this review we focus on comparative the characteristics of both types of atherosclerotic plaques and summarize existing knowledge to provide useful conclusions about current and future treatment strategies. Highlights Carotid and coronary artery disease are two major artherosclerotic conditions. Atherosclerotic plaque development in both locations share similar characteristics. However differences exist regarding risk factors, plaque biology and progression. These differences dictate the different use of diagnostic modalities and treatment goals.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  6. [해외논문]   Lipid-lowering treatment in peripheral artery disease   SCIE

    Katsiki, Niki (Second Department of Propaedeutic Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece ) , Giannoukas, Athanasios D (Department of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece ) , Athyros, Vasilios G (Second Department of Propaedeutic Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece ) , Mikhailidis, Dimitri P (Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, UK)
    Current opinion in pharmacology v.39 ,pp. 19 - 26 , 2018 , 1471-4892 ,

    초록

    Peripheral artery disease (PAD) is characterized by increased cardiovascular (CV) risk, limb morbidity and all-cause mortality. According to the current guidelines (2016) of the American Heart Association/American College of Cardiology on the management of PAD patients, statin therapy is recommended for PAD patients in order to treat dyslipidemia and reduce CV risk. The present narrative review discusses the use of statins and other lipid-lowering drugs such as ezetimibe, fibrates, niacin, anacetrapib and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in PAD patients in terms of both CV and limb outcomes. The clinical implications of hypolipidemic drug therapy in special patient populations including those with metabolic syndrome, non-alcoholic fatty liver disease, chronic kidney disease and type 2 diabetes mellitus, which may frequently co-exist with PAD, are also considered. Highlights Peripheral artery disease (PAD) is characterized by increased cardiovascular risk. Statins remain the first-line lipid-lowering therapy to treat PAD patients. Statins decrease all-cause and cardiovascular death in PAD patients. The role of other lipid-lowering drugs in PAD patients requires further research.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  7. [해외논문]   Cell therapy for peripheral artery disease   SCIE

    Frangogiannis, Nikolaos G
    Current opinion in pharmacology v.39 ,pp. 27 - 34 , 2018 , 1471-4892 ,

    초록

    Patients with severe peripheral artery disease (PAD) who are not candidates for revascularization have poor prognosis. Cell therapy using peripheral blood-derived or bone marrow-derived mononuclear cells, mesenchymal stem cells, or marker-specific subsets of bone marrow cells with angiogenic properties may hold promise for no-option PAD patients. Injected cells may exert beneficial actions by enhancing local angiogenesis (either through maturation of endothelial progenitors, or through secretion of angiogenic mediators), or by transducing cytoprotective signals that preserve tissue structure. Despite extensive research, robust clinical evidence supporting the use of cell therapy in patients with critical limb ischemia is lacking. Larger, well-designed placebo-controlled clinical trials did not support the positive results of smaller less rigorous studies. There is a need for high-quality clinical studies to test the effectiveness of cell therapy in PAD patients. Moreover, fundamental cell biological studies are needed to identify the optimal cell types, and to develop strategies that may enhance homing, survival and effectiveness of the injected cells.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  8. [해외논문]   Anti-hypertensive treatment in peripheral artery disease   SCIE

    Tsioufis, Costas (First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece ) , Andrikou, Ioannis (First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece ) , Siasos, Gerasimos (First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece ) , Filis, Konstantinos (First Department of Propaedeutic Surgery, University of Athens Medical School, Hippocration Hospital, Athens, Greece ) , Tousoulis, Dimitrios (First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece)
    Current opinion in pharmacology v.39 ,pp. 35 - 42 , 2018 , 1471-4892 ,

    초록

    Peripheral artery disease (PAD) affects more than 200 million people worldwide. Hypertension has been related to increased risk of PAD. The treatment of elevated blood pressure (BP) in these patients is indicated to lower the cardiovascular risk with a BP goal of less than 130/80mmHg. Although there is no evidence that one class of antihypertensive medication or strategy is superior for BP lowering in PAD, the use of renin-angiotensin-system (RAS) inhibitors can be effective to reduce the cardiovascular risk. Beta-blockers (BBs) are not contraindicated. In the presence of carotid atherosclerosis, calcium-channel blockers (CCBs) and angiotensin-converting-enzyme inhibitors are recommended. In fibromuscular dysplasia the treatment of choice is percutaneous renal angioplasty. In renal artery disease optimal medical therapy includes RAS inhibitors, CCBs, BBs and diuretics. Highlights A blood pressure goal of less than 130/80mmHg is recommended in PAD. All classes of antihypertensive medication are equal. BBs are not contraindicated. In carotid atherosclerosis, CCBs and ACEIs are recommended. In renal artery disease treatment includes RAS inhibitors, CCBs, BBs, diuretics. In renal artery disease, interventional treatment vs medication is a debated issue. Graphical abstract [DISPLAY OMISSION]

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  9. [해외논문]   Peripheral artery disease and antiplatelet treatment   SCIE

    Tsigkou, Vasiliki (Department of Cardiology, 'Hippokration' General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece ) , Siasos, Gerasimos (Department of Cardiology, 'Hippokration' General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece ) , Rovos, Kleanthis (Department of Cardiology, 'Hippokration' General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece ) , Tripyla, Niki (Department of Cardiology, 'Hippokration' General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece ) , Tousoulis, Dimitris (Department of Cardiology, 'Hippokration' General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece)
    Current opinion in pharmacology v.39 ,pp. 43 - 52 , 2018 , 1471-4892 ,

    초록

    Peripheral artery disease (PAD) is one of the most important causes of cardiovascular morbidity and mortality and its prevalence is alarmingly increasing in modern societies. PAD shares common characteristics with the other atherosclerotic diseases but involves specifically the arteries of the lower extremities. Apart from the changes in lifestyle, antiplatelet agents are the hallmark of the treatment and improve the symptoms as well as the progression of the disease. Aspirin is the cornerstone of treatment and is administrated in doses ranging from 75 to 325mg daily. Additionally, cilostazol and clopidogrel have an important therapeutic role too. Novel antiplatelet agents are the subject of research in both experimental and clinical studies in order to evaluate the efficacy and safety profile. The most important antiplatelet factors which are under investigation are the novel P2Y12 receptor inhibitors prasugrel and ticagrelor. Furthermore, vorapaxar, a protease-activated receptor inhibitor, exhibits antiplatelet properties and has been studied in PAD.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  10. [해외논문]   Antioxidant treatment in peripheral artery disease: the rationale is there, but what about clinical results?   SCIE

    Giannopoulos, Georgios (Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA ) , Angelidis, Christos (Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA ) , Vogiatzi, Georgia (1st Department of Cardiology, University of Athens Medical School, Hippokration Hospital, Athens, Greece ) , Cleman, Michael W (Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA ) , Deftereos, Spyridon (Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA)
    Current opinion in pharmacology v.39 ,pp. 53 - 59 , 2018 , 1471-4892 ,

    초록

    Peripheral arterial disease is a major cause of morbidity and disability and has been consistently associated with an adverse overall prognosis. Oxidative stress has been linked to vascular disease, with several suggested pathogenetic mechanisms, leading to various insults of the arterial wall and, ultimately, to atherothrombotic disease. Considering that the pathophysiological background is quite compelling, attenuation of oxidative processes by means of various substances with antioxidant properties has been conceived as a promising therapeutic target. However, clinical results have been mostly disappointing and ‘antioxidant’ therapies are still far from being integrated into treatment algorithms for vascular disease.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지

논문관련 이미지